Non-thyroidal illness syndrome and SARS-CoV-2-associated multisystem inflammatory syndrome in children.
Adolescent
COVID-19
/ complications
Child
Child, Preschool
Euthyroid Sick Syndromes
/ epidemiology
Female
Humans
Italy
/ epidemiology
Male
Prognosis
Retrospective Studies
SARS-CoV-2
/ physiology
Severity of Illness Index
Systemic Inflammatory Response Syndrome
/ epidemiology
Thyroid Gland
/ physiopathology
Thyrotropin
/ blood
Thyroxine
Triiodothyronine
Children
Multisystem inflammatory syndrome
Non-thyroidal illness syndrome
Overall Severity Score
SARS-CoV-2
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
10
03
2021
accepted:
19
07
2021
pubmed:
28
7
2021
medline:
13
1
2022
entrez:
27
7
2021
Statut:
ppublish
Résumé
COVID-19 disease may result in a severe multisystem inflammatory syndrome in children (MIS-C), which in turn may alter thyroid function (TF). We assessed TF in MIS-C, evaluating its impact on disease severity. We retrospectively considered children admitted with MIS-C to a single pediatric hospital in Milan (November 2019-January 2021). Non-thyroidal illness syndrome (NTIS) was defined as any abnormality in TF tests (FT3, FT4, TSH) in the presence of critical illness and absence of a pre-existing hormonal abnormality. We devised a disease severity score by combining severity scores for each organ involved. Glucose and lipid profiles were also considered. A principal component analysis (PCA) was performed, to characterize the mutual association patterns between TF and disease severity. Of 26 (19 M/7F) patients, median age 10.7 (IQR 5.8-13.3) years, 23 (88.4%) presented with NTIS. A low FT3 level was noted in 15/23 (65.3%), while the other subjects had varying combinations of hormone abnormalities (8/23, 34.7%). Mutually correlated variables related to organ damage and inflammation were represented in the first dimension (PC1) of the PCA. FT3, FT4 and total cholesterol were positively correlated and characterized the second axis (PC2). The third axis (PC3) was characterized by the association of triglycerides, TyG index and HDL cholesterol. TF appeared to be related to lipemic and peripheral insulin resistance profiles. A possible association between catabolic components and severity score was also noted. A low FT3 level is common among MIS-C. TF may be useful to define the impact of MIS-C on children's health and help delineate long term follow-up management and prognosis.
Identifiants
pubmed: 34312809
doi: 10.1007/s40618-021-01647-9
pii: 10.1007/s40618-021-01647-9
pmc: PMC8312710
doi:
Substances chimiques
Triiodothyronine
06LU7C9H1V
Thyrotropin
9002-71-5
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-208Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 1979 Mar 15;300(11):579-84
pubmed: 105290
Clin Endocrinol (Oxf). 2021 Sep;95(3):469-477
pubmed: 33813743
Curr Opin Endocrinol Diabetes Obes. 2019 Oct;26(5):241-249
pubmed: 31343421
SN Compr Clin Med. 2021 Jan 7;:1-10
pubmed: 33432304
Metab Syndr Relat Disord. 2008 Dec;6(4):299-304
pubmed: 19067533
SN Compr Clin Med. 2021;3(1):48-59
pubmed: 33437929
Thyroid. 2021 Jan;31(1):8-11
pubmed: 32600165
Clin Endocrinol (Oxf). 2005 Aug;63(2):197-202
pubmed: 16060914
Endocrinology. 2021 Mar 1;162(3):
pubmed: 33543236
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Front Endocrinol (Lausanne). 2020 Oct 07;11:566439
pubmed: 33117282
J Endocrinol Invest. 2021 Aug;44(8):1553-1570
pubmed: 33583003
Front Public Health. 2021 Jan 20;8:587374
pubmed: 33553089
Rev Endocr Metab Disord. 2021 Jun;22(2):485-491
pubmed: 33843008
Int J Endocrinol. 2016;2016:2157583
pubmed: 27803712
Heart. 2020 Sep;106(18):1445-1446
pubmed: 32719098
Clin Biochem Rev. 2016 May;37(2):85-98
pubmed: 28303073
Rev Endocr Metab Disord. 2021 Dec;22(4):803-815
pubmed: 33241508
Heliyon. 2020 Dec;6(12):e05712
pubmed: 33344794
J Pediatr Surg. 2002 Jun;37(6):877-81
pubmed: 12037754
Sci Rep. 2016 Mar 01;6:22271
pubmed: 26928863
Crit Care Clin. 2019 Apr;35(2):375-388
pubmed: 30784616
Endocr J. 2021 Feb 28;68(2):129-136
pubmed: 33473054
Rev Bras Enferm. 2021 Jan 29;74Suppl 1(Suppl 1):e20200624
pubmed: 33533805
J Pediatr Endocrinol Metab. 2020 May 22;33(6):785-791
pubmed: 32441670
J Endocrinol Invest. 2021 Aug;44(8):1597-1607
pubmed: 33320308
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935
pubmed: 33141191
Front Pediatr. 2019 Sep 26;7:374
pubmed: 31612117
J Am Coll Emerg Physicians Open. 2021 Jan 29;2(1):e12375
pubmed: 33554209
Med Clin North Am. 1995 Jan;79(1):211-24
pubmed: 7808093
Endocrine. 2020 Nov;70(2):348-355
pubmed: 32346815
Ital J Pediatr. 2021 Feb 8;47(1):24
pubmed: 33557873
J Endocrinol Invest. 2021 May;44(5):891-904
pubmed: 33559848
Children (Basel). 2021 Mar 01;8(3):
pubmed: 33804501
Cell Immunol. 2008 Mar-Apr;252(1-2):1-6
pubmed: 18619587
Front Pediatr. 2020 Dec 04;8:605807
pubmed: 33344389
J Pediatr. 2020 Nov;226:45-54.e1
pubmed: 32768466